Zoloft (Sertraline)

Sertraline (Zoloft) is one of the most prescribed antidepressants in the world and the workhorse first-line SSRI in the US for depression, generalised anxiety, panic disorder, social anxiety, OCD, PTSD, and PMDD. If you walk into a GP's office in America with anxiety or depression, this is probably what you'll be offered. It's the SSRI with the broadest set of FDA-approved indications, the best safety profile in pregnancy and breastfeeding, and the cleanest reputation in psychiatry, which is why it's the default choice in women of reproductive age, postpartum, and during pregnancy.

What makes sertraline subtly different from other SSRIs is that on top of blocking serotonin reuptake, it also weakly blocks dopamine reuptake. Whether that's clinically meaningful is debated, but in practice sertraline tends to feel slightly more activating than

Escitalopram (Lexapro) and is often the SSRI of choice when fatigue, anhedonia, or low motivation dominate the picture. It's a prescription drug, takes 4-6 weeks to reach full effect, and stopping abruptly can trigger a real withdrawal syndrome. Not a compound to start or stop casually.

Deep-dive

Sertraline is structurally a tetralin derivative, unrelated to other SSRIs. Its pharmacology has a few quirks that matter clinically.

Serotonin reuptake inhibition. The main mechanism. Sertraline binds the serotonin transporter (SERT) with high affinity and selectivity, blocking serotonin reuptake into the presynaptic neuron and raising synaptic serotonin. The acute serotonin bump isn't the therapeutic effect. Over 2-6 weeks, downstream changes (5-HT1A receptor desensitisation, BDNF upregulation, hippocampal neurogenesis, dendritic remodelling) develop, and these slow adaptations are what actually drive the antidepressant and anti-anxiety response.

Dopamine reuptake inhibition. Sertraline is the only SSRI with meaningful affinity for the dopamine transporter (DAT), with a Ki around 25 nM compared to 0.3 nM at SERT. Whether DAT occupancy is clinically relevant at therapeutic doses is debated, but animal studies show sertraline uniquely raises extracellular dopamine in the nucleus accumbens and striatum where other SSRIs don't. A human vigilance study found that sertraline didn't impair vigilance the way paroxetine did, which the authors attributed to the dopamine effect counteracting serotonin's normal dampening of dopaminergic tone. The practical upshot is that sertraline tends to feel slightly more activating than other SSRIs and may suit people whose depression is dominated by low energy, anhedonia, and amotivation rather than anxiety and rumination.

Sigma-1 receptor. Sertraline binds sigma-1 with reasonable affinity, an effect shared with fluvoxamine (though weaker). Sigma-1 is involved in calcium signalling, neuroplasticity, and ER stress responses, and is part of why sigma-1 active antidepressants are sometimes argued to have additional neuroprotective and anti-inflammatory properties. The evidence is more developed for fluvoxamine than sertraline, and at clinical doses the relevance is unclear.

Depression. Strong evidence base. The 2018 Cipriani network meta-analysis of 522 trials and 116,477 patients ranked sertraline as one of the better-tolerated antidepressants with efficacy roughly comparable to escitalopram, mirtazapine, and venlafaxine. In head-to-head trials, sertraline performs similarly to escitalopram for mood and slightly better for the activating end (energy, motivation), while escitalopram tends to be slightly more sedating. Number needed to treat for response is in the 6-9 range, meaning most people improve but a meaningful minority don't.

Generalised anxiety, panic disorder, social anxiety. Sertraline is effective for GAD and panic disorder in placebo-controlled trials, and it's a first-line option alongside escitalopram and venlafaxine. For panic specifically, start low (12.5-25 mg) because SSRIs commonly worsen panic in the first 1-2 weeks. For social anxiety, sertraline is also FDA-approved and one of the best-studied options. Anxiety symptoms often improve before mood symptoms do.

OCD. Sertraline is one of the first-line SSRIs for OCD, alongside fluvoxamine and fluoxetine. OCD typically needs higher doses than depression (often 150-200 mg/day, sometimes pushed to 300-400 mg/day off-label) and takes longer to respond, usually 8-12 weeks. The 80-week sertraline OCD trial showed sustained efficacy with significantly fewer relapses than placebo, supporting long-term maintenance treatment. CBT plus SSRI tends to outperform either alone for OCD. For severe or treatment-resistant cases, clomipramine is still the most potent option but with worse tolerability.

PTSD. Sertraline and paroxetine are the only two SSRIs FDA-approved for PTSD. The Brady 2000 RCT (187 patients, 12 weeks, 73% women) established sertraline as an effective and well-tolerated PTSD treatment with significant reductions in CAPS scores compared to placebo. Real-world response rates in trauma populations are typically 44-63%. Sertraline is the default pharmacotherapy choice in PTSD, particularly in women, postpartum mothers, and in any combination treatment with trauma-focused psychotherapy. Worth knowing that trauma-focused psychotherapy (prolonged exposure, EMDR, CPT) generally outperforms SSRIs as monotherapy and is the first-line recommendation in most guidelines.

PMDD. Sertraline is one of the best-studied SSRIs for PMDD. Continuous and luteal-phase-only dosing both work, with luteal-phase dosing (starting 14 days before expected menses, stopping at bleed onset) showing comparable efficacy with less total drug exposure. The effect is fast (often within 1-2 cycles) which is unusual for SSRIs and suggests a different mechanism than the slow BDNF-mediated effect in depression, likely direct modulation of allopregnanolone-sensitive GABA signalling. Practical and well-tolerated for the right person.

Pregnancy and breastfeeding. Sertraline has the best safety record of any SSRI in pregnancy and breastfeeding. Pooled breastmilk data show relative infant doses around 0.5-2%, with most breastfed infants having undetectable serum sertraline levels. Placental passage is also low, with cord blood concentrations roughly 33% of maternal levels. Third-trimester SSRI exposure carries a small increased risk of neonatal pulmonary hypertension (around 3 per 1,000 vs 1 per 1,000 baseline) and a transient post-natal adaptation syndrome in around 30% of exposed neonates that resolves within days. The risks of untreated depression in pregnancy (preterm birth, low birth weight, postpartum depression, suicide) are real and have to be weighed against drug exposure. When a woman needs an SSRI in pregnancy or while breastfeeding, sertraline is usually the preferred choice.

Women. Sertraline is one of the better-studied SSRIs in women specifically, partly because of its strong evidence base in PMDD, postpartum depression, and pregnancy. Pharmacokinetic differences between sexes are small and dosing is usually the same. Oestrogen affects serotonin signalling, so SSRI response can vary across the cycle in some women, with perimenopausal and postmenopausal women often noticing more pronounced effects. Hormonal contraception doesn't meaningfully alter sertraline levels. Sexual side effects in women are real and underreported, decreased libido and anorgasmia are common, though sertraline tends to be slightly better on this axis than paroxetine or escitalopram. The historical narrative that women don't get SSRI sexual side effects is just an artefact of not asking.

Older adults. Pharmacokinetics shift modestly with age. Sertraline's half-life and clearance are largely preserved compared to escitalopram, which has bigger age-related shifts. Hyponatraemia risk is still higher in older adults, particularly women on diuretics. Start at 25 mg and titrate slowly, watch sodium in the first month.

Cardiac. Sertraline has a smaller effect on QT interval than citalopram and is considered the safer SSRI in patients with cardiac history. The SADHART trial established sertraline as safe and effective in patients with recent myocardial infarction or unstable angina, which is why it's often the first SSRI considered in cardiac patients.

Sexual side effects. Real, common, and often underdiscussed. Across SSRIs, honest-reporting rates of sexual dysfunction sit around 30-70%. Sertraline is on the lower end of this range, generally less than paroxetine and citalopram but more than bupropion or mirtazapine. Effects include decreased libido, delayed orgasm, anorgasmia, and erectile difficulty. Post-SSRI sexual dysfunction (PSSD), where sexual side effects persist after discontinuation, has been reported with sertraline as with other SSRIs. Prevalence is unclear and mechanism is poorly understood. Worth knowing about before starting.

Emotional blunting. A reduction in emotional reactivity in both directions. Common across SSRIs and one of the most cited reasons people choose to come off long-term treatment. Around 40-60% of long-term SSRI users report some degree of it. Whether it's the drug or residual underlying illness is genuinely debated.

Combinations and stacks. Bupropion is the most common augmentation, used to counter SSRI-induced sexual dysfunction, low energy, and emotional blunting. The sertraline-bupropion combination is well-tolerated and one of the most-prescribed augmentation strategies in psychiatry. Mirtazapine adds when sleep and appetite are problems. Lithium and atypical antipsychotics are used for treatment-resistant depression but are specialist territory.

Comparison to other SSRIs. Versus escitalopram, sertraline tends to be slightly more activating, has more GI side effects (especially diarrhoea), but often less sexual dysfunction. Versus fluvoxamine, sertraline has a vastly cleaner drug interaction profile (fluvoxamine is a strong CYP1A2 inhibitor) but lacks fluvoxamine's stronger sigma-1 mechanism. Versus paroxetine, sertraline has a much milder discontinuation syndrome, less weight gain, and fewer anticholinergic effects. Versus fluoxetine, sertraline works faster and has a shorter half-life, which means missed doses matter more but switching drugs is simpler. If you need an SSRI in pregnancy, breastfeeding, or with cardiac history, sertraline is usually the first pick.

Limits of the evidence. Trials are mostly 8-12 weeks. Long-term efficacy data beyond 1-2 years is thinner, though the OCD relapse-prevention trial extended to 80 weeks. The exact prevalence and predictors of PSSD and persistent post-discontinuation symptoms are unknown. The dopamine reuptake angle is real in animals and pharmacologically plausible in humans but the clinical magnitude is uncertain.

Dosage:

Standard starting dose: 25-50 mg once daily for depression and GAD. Start at 25 mg for the first week if you're prone to anxiety or panic, then move to 50 mg. The most common therapeutic range is 50-100 mg/day

OCD: Higher doses are usually needed. Standard is 50 mg to start, titrate to 150-200 mg/day over 4-8 weeks. Off-label use up to 300-400 mg/day exists for treatment-resistant OCD, but the dose-response curve is shallow above 200 mg

PTSD: Start at 25 mg, titrate to 50-200 mg/day. Average effective dose in trials sits around 100-150 mg

Panic disorder: Start at 12.5-25 mg for the first 1-2 weeks because SSRIs commonly worsen panic at initiation. Target 50-100 mg/day after settling in

PMDD: Either continuous 50-100 mg/day or luteal-phase dosing starting 14 days before expected menses and stopping with bleed onset. Luteal-phase dosing has comparable efficacy with less total drug exposure and is genuinely useful for women who don't want continuous SSRI exposure

Older adults: Start at 25 mg, titrate slowly. Maximum dose is unchanged but tolerability windows narrow. Watch sodium

Take with food. Sertraline bioavailability increases roughly 25-30% when taken with food, which matters more here than for other SSRIs. Make a habit of taking it with the same meal each day for consistent levels

Timing: Morning vs evening depends on whether it makes you sleepy or activated. Sertraline is typically slightly activating so most people take it in the morning, but try one for a week and switch if sleep is disrupted

Time to effect: Anxiety, sleep, and somatic symptoms often improve in 1-2 weeks. Mood and cognitive symptoms take 4-6 weeks. OCD takes 8-12 weeks. Don't judge full response before week 6 (or week 12 for OCD). If there's no movement by then at adequate dose, consider switching or augmenting

Discontinuation: Never stop abruptly. Sertraline has a 26-hour half-life which puts it in the moderate-risk category for discontinuation syndrome, milder than paroxetine and venlafaxine but worse than fluoxetine. Taper by 25 mg every 2-4 weeks. Hyperbolic tapering (smaller proportional reductions as you get lower) is increasingly recommended after long-term use. The last 12.5-25 mg often cause the most withdrawal symptoms, and liquid sertraline or compounded smaller doses are sometimes needed for the final taper

Missing a dose: One missed dose isn't a problem. Two or three in a row can trigger discontinuation symptoms because sertraline's half-life is moderate. Set an alarm if you forget regularly

Alcohol: Not a hard contraindication but the combination amplifies sedation, can blunt the antidepressant effect, and worsens sleep architecture. Moderate use is generally tolerated

Hard contraindications: MAOIs (14-day washout in either direction), pimozide, linezolid, methylene blue. Combining with serotonergic drugs (other SSRIs/SNRIs, MDMA, tramadol, triptans, dextromethorphan, St John's wort, 5-HTP) raises serotonin syndrome risk

Drug interactions to know: Tramadol (serotonin syndrome and lowered seizure threshold), NSAIDs and aspirin (increased bleeding risk), warfarin (variable INR effects), QT-prolonging drugs (additive effect, though sertraline is mild here). Sertraline is metabolised by multiple CYP enzymes (mainly 2B6, 2C19, 3A4, 2D6) so it's less prone to single-pathway interactions than fluvoxamine, but it's also a moderate CYP2D6 inhibitor at higher doses

Here's what you can expect:

The first 1-2 weeks are often the worst. Nausea, diarrhoea, headache, jitteriness, vivid dreams, sleep disruption, transiently increased anxiety, mild GI symptoms. Sertraline is particularly known for GI side effects, diarrhoea especially, which can persist longer than the other early symptoms in some people. Most of it fades by week 3-4. This is the most common period for people to quit before the drug has had a chance to work, so it helps to know it's coming. Starting at 25 mg for the first week, even when the target is 50, makes a meaningful difference for sensitive people.

Real therapeutic benefit comes in stages. Physical symptoms (sleep, appetite, somatic anxiety) often shift first, by week 2-3. Mood, energy, and cognitive symptoms (rumination, hopelessness, difficulty concentrating) shift slower, by week 4-6. For OCD specifically, expect a longer timeline (8-12 weeks) and a smoother trajectory rather than a clear lift. The classic pattern with depression is that people feel more capable of action before they feel happier, which is one reason the early weeks have a slightly increased risk of self-harm in vulnerable people, the depression hasn't lifted but the inertia has.

By month 2-3 most people have reached a stable state where the underlying symptom load is meaningfully lower and the side effects have settled into whatever the long-term baseline is going to be. Sexual side effects and emotional blunting usually persist as long as you're on the drug. GI symptoms, headaches, and sleep changes usually don't.

Most people stay on sertraline for somewhere between 6 months and several years. The official recommendation for a first depressive episode is at least 6-9 months after full remission. For recurrent depression, anxiety, OCD, or PTSD, longer-term treatment is the norm. The decision of when to come off is genuinely hard and worth having with a prescriber rather than figuring out solo.

Side effects & risks:

GI symptoms are the most common early side effects, especially nausea and diarrhoea. Sertraline causes diarrhoea more than other SSRIs, affecting around 15-20% of people. Taking with food helps with nausea. Usually settles by week 3-4 but diarrhoea can persist longer

Sleep disruption. Insomnia or vivid dreams in some, sedation in others. Sertraline tends to be slightly activating, so morning dosing is the default. If it's sedating, switch to evening

Sexual dysfunction. Decreased libido, delayed orgasm, anorgasmia, erectile difficulty. Real-world rates are around 30-50% when patients are asked directly. Sertraline is on the lower end of the SSRI class for sexual side effects but it's still common. Usually persists for the duration of treatment. Bupropion augmentation, dose reduction, and drug holidays are sometimes used to manage it, with mixed results

Post-SSRI sexual dysfunction (PSSD). A small population reports sexual side effects persisting months or years after stopping. Mechanism isn't understood, prevalence isn't well established, no proven treatment. Worth knowing exists

Emotional blunting. Reduced reactivity in both directions. Hard to capture in trials but common in real-world reports. The most cited reason people choose to come off long-term

Weight gain. Modest, around 1-3 kg over 6-12 months on average, sometimes more. Less than mirtazapine or paroxetine, similar to escitalopram

Sweating (antidepressant-induced excessive sweating). Dose-related, usually mild

Yawning. Weird but well-documented side effect across SSRIs, harmless

Increased bleeding risk. SSRIs reduce platelet serotonin uptake, mildly impairing platelet function. Clinically relevant with NSAIDs, aspirin, anticoagulants, or perioperatively. Tell your surgeon before any procedure

Hyponatraemia (low sodium). Uncommon but can be serious. More frequent in older adults, women, low body weight, and those on diuretics. Usually appears in the first month

QT prolongation. Smaller than citalopram, generally considered safe even in cardiac patients. Worth a baseline ECG if you have significant cardiac history

Bruxism (teeth grinding). Common and underdiscussed, can damage teeth over time. Often manageable with a night guard, dose reduction, or low-dose buspirone

Activation and increased anxiety in the first 2 weeks. Counterintuitive but common, especially in panic-prone people. Usually transient. Starting at 25 mg mitigates this

Suicidal ideation in young people. SSRIs carry a black-box warning for increased suicidal thoughts in patients under 25 during the first weeks. Risk is highest at initiation and dose changes, and is partly counterbalanced by the protective effect of treating the underlying disorder. Worth honest conversation if relevant

Discontinuation syndrome. Common with abrupt cessation. Symptoms include dizziness, electric-shock sensations ("brain zaps"), nausea, irritability, vivid dreams, flu-like feelings. Usually peaks 2-5 days after stopping and resolves over 1-3 weeks, though a minority experience symptoms for much longer. Always taper, and slowly

Serotonin syndrome. Potentially life-threatening reaction from excessive serotonergic activity. Risk rises with combinations (MAOIs, other SSRIs/SNRIs, tramadol, triptans, MDMA, dextromethorphan, linezolid, St John's wort). Symptoms include agitation, tremor, hyperthermia, autonomic instability, clonus

Mania switch. In people with undiagnosed bipolar disorder, SSRIs can trigger manic or hypomanic episodes. Worth screening for bipolar history before starting

🩸

Blood markers

Sodium, baseline before starting and at 2-4 weeks if you're over 65, female, low body weight, or on a diuretic. SSRI-induced hyponatraemia usually appears in the first month and can be serious if missed.

Liver enzymes (ALT, AST), baseline. Sertraline is hepatically metabolised through multiple CYP enzymes, and clearance shifts with significant liver dysfunction. Recheck if symptoms suggest hepatic strain.

ECG, baseline if you have cardiac history or are on other QT-prolonging medications. Sertraline is one of the safer SSRIs for cardiac patients but a baseline reference is worth having.

TSH and free T4, baseline. Hypothyroidism can present as treatment-resistant depression, so rule it out before committing to long-term SSRI treatment.

CYP2C19 genotype is occasionally useful. Sertraline metabolism is less CYP2C19-dependent than escitalopram, but variants can still shift exposure modestly. Not routine testing but worth knowing about if you're getting unusually strong side effects at standard doses.

Pregnancy test, before starting in women of reproductive age. Sertraline has the best safety profile of any SSRI in pregnancy, but the decision is still individualised and depends on knowing the situation.

For most healthy adults starting sertraline, baseline sodium, liver enzymes, and TSH cover the meaningful ground. The bloodwork that actually matters most isn't standard chemistry, it's tracking response and side effects week to week with your prescriber and being honest about what's happening, including the awkward stuff.

Sertraline is a prescription drug in essentially all jurisdictions.